134 related articles for article (PubMed ID: 2968836)
1. Treatment of experimental ovarian carcinoma with monthly injection of the agonist D-Trp-6-LH-RH: a preliminary report.
Pour PM; Redding TW; Paz-Bouza JI; Schally AV
Cancer Lett; 1988 Jul; 41(1):105-10. PubMed ID: 2968836
[TBL] [Abstract][Full Text] [Related]
2. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.
Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
Cancer Res; 1990 Jun; 50(12):3716-21. PubMed ID: 2160323
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Schally AV; Redding TW
Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
[TBL] [Abstract][Full Text] [Related]
4. Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp-6-LH-RH and somatostatin analog RC-160. Histological evidence of improvement.
Zalatnai A; Schally AV
Int J Pancreatol; 1989 Mar; 4(2):149-60. PubMed ID: 2566638
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
Yano T; Pinski J; Halmos G; Szepeshazi K; Groot K; Schally AV
Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7090-4. PubMed ID: 7518926
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.
Torres-Aleman I; Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1252-6. PubMed ID: 2858096
[TBL] [Abstract][Full Text] [Related]
7. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.
Szende B; Zalatnai A; Schally AV
Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1643-7. PubMed ID: 2564204
[TBL] [Abstract][Full Text] [Related]
8. Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules.
Zalatnai A; Schally AV
Cancer Res; 1989 Apr; 49(7):1810-5. PubMed ID: 2564312
[TBL] [Abstract][Full Text] [Related]
9. Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH.
Gonzalez-Barcena D; Perez-Sanchez P; Berea-Dominguez H; Graef-Sanchez A; Becerril-Morales M; Comaru-Schally AM; Schally AV
Prostate; 1986; 9(2):207-15. PubMed ID: 2944084
[TBL] [Abstract][Full Text] [Related]
10. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone.
Paz-Bouza JI; Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1987 Feb; 84(4):1112-6. PubMed ID: 2881296
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
Redding TW; Schally AV
Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
[TBL] [Abstract][Full Text] [Related]
12. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
Schally AV; Kook AI; Monje E; Redding TW; Paz-Bouza JI
Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression.
Szende B; Srkalovic G; Schally AV; Lapis K; Groot K
Cancer; 1990 May; 65(10):2279-90. PubMed ID: 1971771
[TBL] [Abstract][Full Text] [Related]
14. LH-RH agonists and antagonists.
Schally AV; Coy DH; Arimura A
Int J Gynaecol Obstet; 1980; 18(5):318-24. PubMed ID: 6110575
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
Yano T; Pinski J; Radulovic S; Schally AV
Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1701-5. PubMed ID: 8127868
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma.
Gonzalez-Barcena D; Perez-Sanchez PL; Graef A; Gomez AM; Berea H; Comaru-Schally AM; Schally AV
Prostate; 1989; 14(4):291-300. PubMed ID: 2526325
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
Halmos G; Schally AV; Kahan Z
Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548
[TBL] [Abstract][Full Text] [Related]
18. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
Fekete M; Zalatnai A; Schally AV
Cancer Lett; 1989 May; 45(2):87-91. PubMed ID: 2567204
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of growth of a prolactin-secreting pituitary tumor in rats by analogs of luteinizing hormone-releasing hormone and somatostatin.
de Quijada MG; Redding TW; Coy DH; Torres-Aleman I; Schally AV
Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3485-8. PubMed ID: 6134284
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1983 Mar; 80(5):1459-62. PubMed ID: 6219395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]